10-Q: USANA Health Sciences Reports Q3 2026 Results, Faces Sales Decline

USANA Health Sciences reported a 3.6% decrease in net sales for the third quarter of 2026, alongside a significant goodwill impairment charge and a net loss.

Summary

• USANA Health Sciences reported net sales of $205.9 million for the third quarter of 2026, a 3.6% decrease compared to the prior year's quarter.
• The company incurred a net loss of $5.6 million for the quarter, an improvement from the $6.5 million net loss in the prior year, primarily due to lower operating expenses.
• A significant goodwill impairment charge of $29.1 million was recorded in the second quarter of 2026 related to the Hiya reporting unit.
• Active customers in the Core Nutritional business decreased by 8.2% year-over-year.
• The company's cash and cash equivalents increased to $178.9 million as of October 3, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to declining sales, significant goodwill impairment, and a net loss, despite some operational efficiencies.

Positives

• Net loss attributable to USANA improved to $5.6 million from $6.5 million in the prior-year quarter.
• Consolidated gross profit margin remained strong at 76.3% for the quarter.
• Hiya segment gross margins increased by 170 basis points to 66.1%, reflecting savings in shipping and decreased inventory scrap costs.
• Cash and cash equivalents increased to $178.9 million as of October 3, 2026, from $158.4 million as of January 3, 2026.
• The company has $33.965 million remaining under its stock repurchase plan.

Negatives

• Net sales decreased by 3.6% to $205.9 million in Q3 2026 compared to Q3 2025.
• A goodwill impairment charge of $29.1 million was recognized in Q2 2026 for the Hiya reporting unit.
• Net loss attributable to USANA was $5.6 million for the quarter, and $19.4 million for the nine months ended October 3, 2026.
• Active customers in the Core Nutritional business decreased by 8.2% year-over-year.
• Rise segment net sales decreased by 44.8% in Q3 2026 compared to the prior year.
• Hiya segment experienced an increase in relative selling, general and administrative expenses from 66.5% to 86.2% of segment net sales.

Risks

• Dependence on the Core Nutritional and direct sales business model, which has experienced declines in net sales, net income, and active customers.
• Evolution to an omni-channel health and wellness company with dependence on acquired DTC businesses (Hiya and Rise) for growth outside the Core Nutritional business.
• Extensive regulation of the Core Nutritional business and uncertainties in interpreting and enforcing laws governing direct selling and anti-pyramiding.
• Operational risks in China, including direct selling regulations, data privacy, and economic changes.
• Product liability claims and litigation associated with products.
• Macroeconomic conditions, including inflationary pressures, slower economic growth, and supply chain disruptions.
• Challenges in Hiya's growth strategy, including expansion into new channels and adapting to digital marketing changes.
• Political events, natural disasters, pandemics, or health crises impacting economic conditions and consumer behavior.

Future Outlook

The company believes its current cash balances, future cash provided by operations, and amounts available under its line of credit will be sufficient to cover operating and capital needs. However, it acknowledges that additional financing may be required if an adverse operating environment or unanticipated capital expenditure requirements arise. Potential financing could include debt or equity, which may result in dilution to existing shareholders.

Management Comments

• The company's Core Nutritional business is its primary business, accounting for approximately 83% of consolidated net sales during the nine months ended October 3, 2026.
• USANA's vision is to improve the overall health and nutrition of individuals and families worldwide.
• The company remains confident in the future of Hiya and recognizes its strategic importance as part of the Company's consolidated long-term growth strategy.
• Management believes that maintaining a capital structure emphasizing sufficient liquidity and adaptability is a top priority.

Industry Context

StockSavvy.ai notes that USANA's performance reflects broader challenges in the direct-selling and health & wellness sectors, including increased competition, evolving consumer preferences towards omni-channel purchasing, and the impact of digital marketing shifts. The significant goodwill impairment highlights the integration challenges and performance expectations for acquired entities like Hiya.

Comparison to Industry Standards

• Direct selling companies often face challenges with customer acquisition and retention, as indicated by USANA's 8.2% decline in active Core Nutritional customers.
• The health and wellness industry is highly competitive, with companies like Herbalife Nutrition and Nu Skin Enterprises also operating in similar direct-selling models, though their recent performance may vary.
• Acquisitions in the consumer goods sector, particularly in health and wellness, often carry integration risks and potential for goodwill impairment if performance targets are not met, as seen with Hiya.
• The shift towards direct-to-consumer (DTC) and omni-channel strategies is a significant trend across many consumer industries, requiring companies to adapt their distribution and marketing approaches.

Legal Proceedings

• The company is involved in various lawsuits, claims, and other legal matters arising in the ordinary course of business, including those related to products, intellectual property, supplier relationships, distributors, competitors, and employees. Management does not currently believe these matters, individually or in aggregate, will have a material adverse effect on the company's financial condition, liquidity, or results of operations.

Stakeholder Impact

• Shareholders: Potential dilution from future equity financing, impact of net loss and goodwill impairment on stock price.
• Brand Partners: Continued focus on compensation plans and sales strategies to support their business growth.
• Customers: Potential impact of product availability and pricing, though no direct negative impacts are highlighted.
• Suppliers: Continued demand for raw materials and finished goods, subject to supply chain stability.
• Creditors: Covenants in the credit facility require minimum EBITDA of $70,000 for the fiscal quarter ending October 3, 2026, and a funded debt to EBITDA ratio of less than or equal to 2.0 to 1.0.

Next Steps

• Continue to evaluate and adapt the omni-channel strategy across Core Nutritional, Hiya, and Rise segments.
• Focus on increasing the number of active customers and average spend per customer.
• Manage operating expenses and pursue cost realignment initiatives.
• Monitor and adapt to evolving digital marketing environments and consumer behavior.
• Continue to assess potential acquisition opportunities and investments.

Key Dates

Recommendation

While the company shows some operational improvements and a stronger cash position, the declining sales, significant goodwill impairment, and continued net losses indicate ongoing challenges. The strategic shift to an omni-channel model and the performance of acquired entities like Hiya require further observation. A 'hold' recommendation reflects a cautious approach pending signs of sustained sales recovery and improved profitability.

Keywords

USANA Health Sciences, Nutritional Supplements, Direct Selling, Health and Wellness, Omni-channel, Goodwill Impairment, Q3 Earnings, Financial Results